Cure8 research brief
This study highlights factors—tumor location, age, smoking, and having IBD—that were associated with survival and progression in a Lebanese CRC cohort.
Those with IBD or who smoke may be at higher risk of worse outcomes, and tumor molecular features (KRAS/BRAF, MMR) were measured, which can influence treatment planning.
Clinicians treating colorectal cancer, oncology researchers, patients with colorectal cancer, and patients with inflammatory bowel disease interested in cancer risk.
This abstract reports a single-center retrospective study of 349 Lebanese patients with colorectal cancer (CRC) diagnosed 2019–2023. The authors analyzed tumor histology, stage, mismatch-repair (MMR) testing, KRAS and BRAF mutation rates, and survival outcomes (OS, PFS, DFS) using Kaplan–Meier and Cox regression.
Key reported findings in the abstract: most tumors were low-grade adenocarcinomas; a high proportion presented with stage III/IV disease; 5.5% were dMMR among those tested; KRAS mutations were present in ~43% and BRAF in ~7% of patients tested.
Smoking and older age were associated with worse overall survival, inflammatory bowel disease was linked to higher risk of progression, and left-sided tumors were associated with better overall survival. The study is framed as supporting risk-adapted screening and population-specific treatment approaches in the Middle East.
This note is based on the article abstract provided and does not reflect review of the full article text beyond the abstract.
Single-center, retrospective design with results reported from the article abstract. Molecular testing and MMR status were available only for subsets of patients; findings may not generalize beyond the studied population or region.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
